Dataset Information


Comparative analysis of the DYRK1A-SRSF6-TNNT2 pathway in myocardial tissue from individuals with and without Down syndrome.

ABSTRACT: Down syndrome (trisomy 21) is characterized by genome-wide imbalances that result in a range of phenotypic manifestations. Altered expression of DYRK1A in the trisomic context has been linked to some Down syndrome phenotypes. DYRK1A regulates the splicing of cardiac troponin (TNNT2) through a pathway mediated by the master splicing factor SRSF6. Here, we documented the expression of the DYRK1A-SRSF6-TNNT2 pathway in a collection of myocardial samples from persons with and without Down syndrome. Results suggest that "gene dosage effect" may drive the expression of DYRK1A mRNA but has no effect on DYRK1A protein levels in trisomic myocardium. The levels of phosphorylated DYRK1A-Tyr321 tended to be higher (~35%) in myocardial samples from donors with Down syndrome. The levels of phosphorylated SRSF6 were 2.6-fold higher in trisomic myocardium. In line, the expression of fetal TNNT2 variants was higher in myocardial tissue with trisomy 21. These data provide a representative picture on the extent of inter-individual variation in myocardial DYRK1A-SRSF6-TNNT2 expression in the context of Down syndrome.

SUBMITTER: Quinones-Lombrana A 

PROVIDER: S-EPMC6754281 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC6049609 | BioStudies
2012-01-01 | S-EPMC3314962 | BioStudies
2008-01-01 | S-EPMC2556438 | BioStudies
1000-01-01 | S-EPMC5809559 | BioStudies
2019-01-01 | S-EPMC6873902 | BioStudies
2019-01-01 | S-EPMC6629165 | BioStudies
2019-01-01 | S-EPMC6408590 | BioStudies
2008-01-01 | S-EPMC2677016 | BioStudies
2018-01-01 | S-EPMC5870938 | BioStudies
2017-01-01 | S-EPMC5606891 | BioStudies